Navigation Links
VaxGen Restructures Board of Directors
Date:5/22/2008

Governance changes intended to support renewed strategic transaction effort

SOUTH SAN FRANCISCO, Calif., May 22 /PRNewswire-FirstCall/ VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today announced the appointment of two new members to its Board of Directors, and the resignations of three of its current Directors. The new Board appointees are Paul De Stefano, J.D., a principal with the law firm of Fish and Richardson LLC, and a specialist in transactions in the biotechnology and health sciences industries; and Lori F. Rafield, Ph.D., currently an independent consultant specializing in corporate and business development for biotechnology companies and previously a Managing Director with the venture firm of Apax Partners. The Board members resigning are VaxGen's current chairman Randall L-W. Caudill D.Phil., Michel Greco and Myron M. Levine, M.D.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

In conjunction with these changes, VaxGen is reconstituting the Strategic Transactions Committee of the Board. De Stefano and Rafield will serve on this Committee, together with James P. Panek, VaxGen's President and CEO. De Stefano will also be a member of the Board's Audit and Nominating and Governance Committees, while Rafield will serve on the Compensation Committee. Kevin Reilly has been elected Chairman of the Board to replace Dr. Caudill.

"Both Paul and Lori have decades of biotechnology transaction experience." said James P. Panek, VaxGen President and CEO. "I am delighted to welcome two such well-qualified Directors, and look forward to working closely with them as the Company re-evaluates its strategic alternatives. With these governance changes, I believe we are well positioned to move forward on a renewed strategic transaction effort. I'd also like to thank Randall, Michel and Myron for their capable guidance and dedicated service over the past several years."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding VaxGen's intent to pursue a strategic transaction. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007, and any subsequently filed Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... , April 27, 2017  Kinexum, a distinguished resource ... today announces the appointment of Thomas C. Seoh ... ("Zan") Fleming, M.D., Kinexum founder, who becomes Executive Chairman ... to Kinexum clients. Thomas Seoh ... the Kinexum mission and lead the firm,s remarkable team ...
(Date:4/26/2017)... Alto, CA, USA (PRWEB) , ... April 26, ... ... popular seminar on FDA’s GMP expectations for phase I clinical trials comes to ... attended by various biotechnology and pharma professionals representing FDA regulated organizations such as ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... in EMEA and North America this May on the ... 16-18 , Donald H. Taylor, Chairman of the Learning and Performance Institute will ...
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the Stago EdVantage Virtual ... testing for DIC in order to illuminate this clinical problem for people unfamiliar with ... patients resulting in a high degree of morbidity and mortality. DIC is a confusing ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):